Profile data is unavailable for this security.
About the company
Candel Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing off-the-shelf multimodal biological immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. The Company has established two clinical-stage multimodal biological immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) gene constructs, respectively. CAN-2409 is the lead product candidate from the adenovirus platform and is in ongoing clinical trials in non-small cell lung cancer (NSCLC), borderline resectable pancreatic cancer, and localized, non-metastatic prostate cancer. CAN-3110 is the lead product candidate from the HSV platform and is in an ongoing investigator-sponsored phase I clinical trial in recurrent high-grade glioma (HGG). Its enLIGHTEN Discovery Platform leverages human biology and advanced analytics to create new viral immunotherapies for solid tumors.
- Revenue in USD (TTM)0.00
- Net income in USD-49.99m
- Incorporated2003
- Employees42.00
- LocationCandel Therapeutics Inc117 Kendrick Street,, Suite 450NEEDHAM 02494United StatesUSA
- Phone+1 (617) 916-5445
- Fax+1 (302) 655-5049
- Websitehttps://www.candeltx.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Vigil Neuroscience Inc | 0.00 | -83.84m | 141.54m | 64.00 | -- | 1.57 | -- | -- | -2.12 | -2.12 | 0.00 | 2.27 | 0.00 | -- | -- | 0.00 | -59.07 | -- | -63.28 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -20.98 | -- | -- | -- |
| Cardiff Oncology Inc | 665.00k | -40.88m | 143.37m | 31.00 | -- | 2.68 | -- | 215.60 | -0.9142 | -0.9142 | 0.0149 | 1.15 | 0.0081 | -- | 2.17 | 21,451.61 | -49.98 | -31.24 | -57.60 | -33.56 | -- | -- | -6,143.91 | -7,819.23 | -- | -- | 0.00 | -- | 26.42 | 5.22 | -7.07 | -- | 157.91 | -- |
| Inovio Pharmaceuticals Inc | 591.86k | -121.64m | 143.84m | 122.00 | -- | 1.49 | -- | 243.03 | -5.11 | -5.11 | 0.0248 | 3.73 | 0.0032 | -- | 0.6652 | 4,851.31 | -66.32 | -59.52 | -84.33 | -71.29 | -- | -- | -20,552.24 | -4,097.36 | -- | -- | 0.00 | -- | -91.89 | -51.33 | 51.71 | -- | -31.22 | -- |
| Context Therapeutics Inc | 0.00 | -18.57m | 146.25m | 5.00 | -- | 1.45 | -- | -- | -1.06 | -1.06 | 0.00 | 1.35 | 0.00 | -- | -- | 0.00 | -28.46 | -- | -29.68 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -61.53 | -- | -- | -- |
| Outlook Therapeutics Inc | 0.00 | -94.05m | 149.50m | 24.00 | -- | -- | -- | -- | -8.12 | -8.12 | 0.00 | -3.57 | 0.00 | -- | -- | 0.00 | -205.48 | -214.69 | -- | -1,843.48 | -- | -- | -- | -3,043.92 | -- | -26.89 | -- | -- | -- | -- | 10.70 | -- | -- | -- |
| CytoDyn Inc | 0.00 | -20.53m | 150.01m | 9.00 | -- | -- | -- | -- | -0.0241 | -0.0241 | 0.00 | -0.0699 | 0.00 | -- | -- | 0.00 | -94.20 | -259.15 | -- | -- | -- | -- | -- | -232,918.20 | -- | 1.36 | -- | -- | -- | -- | 35.70 | -- | -- | -- |
| Generation Bio Co | 18.58m | -145.47m | 150.95m | 174.00 | -- | 1.44 | -- | 8.12 | -2.19 | -2.19 | 0.2797 | 1.56 | 0.059 | -- | 56.31 | 106,793.10 | -46.16 | -36.96 | -51.29 | -39.21 | -- | -- | -782.87 | -8,879.44 | -- | -- | 0.00 | -- | -- | 177.31 | 7.34 | -- | 19.61 | -- |
| Checkpoint Therapeutics Inc | 78.00k | -42.47m | 151.71m | 23.00 | -- | -- | -- | 1,945.00 | -1.50 | -1.50 | 0.0027 | -0.372 | 0.0111 | -- | 2.17 | 3,391.30 | -606.33 | -142.43 | -- | -342.79 | -- | -- | -54,444.87 | -6,554.97 | -- | -- | -- | -- | -46.35 | -50.61 | 17.21 | -- | -- | -- |
| Repare Therapeutics Inc | 66.52m | -84.05m | 152.38m | 179.00 | -- | 0.8723 | -- | 2.29 | -2.00 | -2.00 | 1.56 | 4.12 | 0.270 | -- | 3.95 | 371,642.50 | -34.11 | -23.40 | -40.73 | -26.37 | -- | -- | -126.34 | -162.76 | -- | -- | 0.00 | -- | -61.21 | -- | -222.91 | -- | 27.16 | -- |
| Candel Therapeutics Inc | 0.00 | -49.99m | 154.97m | 42.00 | -- | -- | -- | -- | -1.70 | -1.70 | 0.00 | -0.321 | 0.00 | -- | -- | 0.00 | -117.35 | -- | -158.61 | -- | -- | -- | -- | -- | -- | -32.70 | 2.36 | -- | -100.00 | -- | -101.87 | -- | -- | -- |
| Ventyx Biosciences Inc | 0.00 | -152.52m | 155.47m | 75.00 | -- | 0.5577 | -- | -- | -2.37 | -2.37 | 0.00 | 3.94 | 0.00 | -- | -- | 0.00 | -48.98 | -- | -52.21 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -77.97 | -- | -- | -- |
| Vaxart Inc | 13.93m | -75.66m | 155.91m | 109.00 | -- | 1.95 | -- | 11.19 | -0.4707 | -0.4707 | 0.0861 | 0.3518 | 0.1178 | -- | 5.80 | 127,779.80 | -64.01 | -49.60 | -73.18 | -54.86 | -- | -- | -543.21 | -1,398.00 | -- | -226.73 | 0.0507 | -- | 6,796.26 | 12.15 | 23.47 | -- | 21.49 | -- |
| Achieve Life Sciences Inc | 0.00 | -27.54m | 159.00m | 22.00 | -- | 3.76 | -- | -- | -1.10 | -1.10 | 0.00 | 1.23 | 0.00 | -- | -- | 0.00 | -58.78 | -86.31 | -71.94 | -119.59 | -- | -- | -- | -- | -- | -11.79 | 0.294 | -- | -- | -- | 29.60 | -- | -14.51 | -- |
| PepGen Inc | 0.00 | -89.14m | 163.27m | 64.00 | -- | 1.05 | -- | -- | -3.30 | -3.30 | 0.00 | 4.78 | 0.00 | -- | -- | 0.00 | -47.47 | -- | -52.97 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -13.78 | -- | -- | -- |
| Adverum Biotechnologies Inc | 0.00 | -99.86m | 166.42m | 121.00 | -- | 0.9904 | -- | -- | -7.99 | -7.99 | 0.00 | 8.08 | 0.00 | -- | -- | 0.00 | -40.33 | -36.39 | -46.64 | -39.04 | -- | -- | -- | -5,279.60 | -- | -- | 0.00 | -- | -- | 17.43 | 24.18 | -- | -0.0247 | -- |
Data as of Nov 08 2024. Currency figures normalised to Candel Therapeutics Inc's reporting currency: US Dollar USD
10.64%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 30 Jun 2024 | 781.77k | 2.44% |
| BlackRock Fund Advisorsas of 30 Jun 2024 | 749.80k | 2.34% |
| SSgA Funds Management, Inc.as of 30 Jun 2024 | 472.80k | 1.47% |
| Banor Capital Ltd.as of 31 Mar 2024 | 398.83k | 1.24% |
| Geode Capital Management LLCas of 30 Jun 2024 | 397.89k | 1.24% |
| Teachers Advisors LLCas of 30 Jun 2024 | 292.44k | 0.91% |
| TIAA-CREF Investment Management LLCas of 30 Jun 2024 | 89.75k | 0.28% |
| Bridgeway Capital Management LLCas of 30 Jun 2024 | 80.60k | 0.25% |
| Baystate Wealth Management LLCas of 31 Dec 2023 | 76.91k | 0.24% |
| MML Investors Services LLCas of 30 Jun 2024 | 73.38k | 0.23% |
More ▼
Data from 31 Dec 2023 - 30 Sep 2024Source: FactSet Research Systems Inc.
